Ilan Daskal - 01 Sep 2023 Form 4 Insider Report for BIO-RAD LABORATORIES, INC. (BIO)

Reporting relationship: EVP, Chief Financial Officer
Issuer ticker: BIO
Reported as of: 01 Sep 2023
Net transaction value: -$283,323
SEC form: 4
Accepted by SEC: 06 Sep 2023, 13:00:02 UTC
Prior SEC filing: 11 Apr 2023
Next SEC filing: 14 Nov 2023
Source filing: View source filing
Reporting owner signature: /s/ Ilan Daskal

Key filing fact

Ilan Daskal filed Form 4 for BIO-RAD LABORATORIES, INC. (BIO) on 06 Sep 2023.

Key facts

This page summarizes Ilan Daskal's Form 4 filing for BIO-RAD LABORATORIES, INC. (BIO).
10 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 06 Sep 2023, 13:00.

Change

Previous filing in this sequence was filed on 11 Apr 2023.
Current net transaction value: -$283,323.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BIO transaction

Bio-Rad A Common Stock

Options Exercise

Transaction value: $0
Shares: +694
Change %: +46%
Price: $0.000000
Shares after: 2,206
Date: 01 Sep 2023
Ownership: Direct
Footnotes: F1, F2

BIO transaction

Bio-Rad A Common Stock

Tax liability

Transaction value: $94,704
Shares: -240
Change %: -11%
Price: $394.60
Shares after: 1,966
Date: 01 Sep 2023
Ownership: Direct

BIO transaction

Bio-Rad A Common Stock

Options Exercise

Transaction value: $0
Shares: +456
Change %: +23%
Price: $0.000000
Shares after: 2,422
Date: 01 Sep 2023
Ownership: Direct
Footnotes: F1

BIO transaction

Bio-Rad A Common Stock

Tax liability

Transaction value: $82,471
Shares: -209
Change %: -8.6%
Price: $394.60
Shares after: 2,213
Date: 01 Sep 2023
Ownership: Direct

BIO transaction

Bio-Rad A Common Stock

Options Exercise

Transaction value: $0
Shares: +542
Change %: +24%
Price: $0.000000
Shares after: 2,755
Date: 02 Sep 2023
Ownership: Direct
Footnotes: F1

BIO transaction

Bio-Rad A Common Stock

Tax liability

Transaction value: $106,147
Shares: -269
Change %: -9.8%
Price: $394.60
Shares after: 2,486
Date: 02 Sep 2023
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BIO transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +4,007
Change %
Price: $0.000000
Shares after: 4,007
Date: 01 Sep 2023
Ownership: Direct
Underlying class: Bio-Rad A Common Stock
Underlying amount: 4,007
Exercise price: $0.000000
Footnotes: F3, F4

BIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -694
Change %: -25%
Price: $0.000000
Shares after: 2,082
Date: 01 Sep 2023
Ownership: Direct
Underlying class: Bio-Rad A Common Stock
Underlying amount: 694
Exercise price: $0.000000
Footnotes: F3, F5

BIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -456
Change %: -33%
Price: $0.000000
Shares after: 912
Date: 01 Sep 2023
Ownership: Direct
Underlying class: Bio-Rad A Common Stock
Underlying amount: 456
Exercise price: $0.000000
Footnotes: F3, F6

BIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -542
Change %: -50%
Price: $0.000000
Shares after: 542
Date: 02 Sep 2023
Ownership: Direct
Underlying class: Bio-Rad A Common Stock
Underlying amount: 542
Exercise price: $0.000000
Footnotes: F3, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

Shares of Class A common stock acquired on the vesting of restricted stock units.

Footnote F2

Includes 18.9440 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2023.

Footnote F3

Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

Footnote F4

The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

Footnote F5

On September 1, 2022, the reporting person was granted 2,776 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Footnote F6

On September 1, 2021, the reporting person was granted 1,823 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Footnote F7

On September 2, 2020, the reporting person was granted 2,166 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.